MetaCap

Sagimet Biosciences Inc. Series A (SGMT)

NASDAQ: SGMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

9.08-0.54 (-5.61%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SGMT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$648.02M
EPS (TTM)
-$1.18
52-week range
4.50 – 11.45
Day range
8.83 – 9.40
Volume / Avg
1.50M / 1.23M
Beta
—

52-week range

$4.50$11.45

SGMT stock today

Shares of Sagimet Biosciences Series A (SGMT) finished lower on Nov 20 at $9.08, a drop of 5.61% or $0.54 per share, versus the S&P 500's 3.70% decline. Shares are 20.7% below their 52-week high of $11.45, set on Sep 10, 2026 and 101.8% above the 52-week low of $4.50, in the middle of the past year's range. SGMT is up 53.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 36.1%.

Sagimet Biosciences Series A has posted a net loss over the last twelve months (EPS of -$1.18), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Sagimet Biosciences Series A

Company profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. David A. Happel
Headquarters
San Mateo, CA
Employees
16
IPO year
2023

Financial highlights

Full financials

Sagimet Biosciences Series A reported a net loss of $51.0 million, compared with a loss of $45.6 million a year earlier. Diluted earnings per share came in at -$1.58.

Sagimet Biosciences Series A annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue——$2.00M—
Growth————
Net income$-51.04M$-45.57M$-27.88M$-30.50M
EPS (diluted)$-1.58$-1.45$-2.66$-165.20

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$27.27+200.33%

  • Strong buy 2
  • Buy 9
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $7.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.31 vs $-0.25
Surprise
-24.00%

SGMT news

All SGMT news

Sagimet Biosciences Series A peers

Health Care sector
SGMT peer companies
CompanyPrice% ChgMarket capCompare
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs SGMT
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs SGMT
APMDApnimed Inc.16.09-6.70%$669.84Mvs SGMT
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs SGMT
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs SGMT
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs SGMT
LXRXLexicon Pharmaceuticals Inc.1.53-8.38%$681.21Mvs SGMT
ANNXAnnexon Inc.3.10-9.09%$591.37Mvs SGMT

Indexes, lists and sector

Sagimet Biosciences Series A stock FAQ

What is Sagimet Biosciences Series A's stock price today?

SGMT last traded at $9.08 as of Nov 20, 4:00 PM EST, down 5.61% on the day. Prices are delayed at least 15 minutes.

Who is Sagimet Biosciences Series A's CEO?

Mr. David A. Happel is the chief executive officer of Sagimet Biosciences Inc. Series A, which has about 16 employees.

What is the SGMT 52-week high?

The 52-week high for SGMT is $11.45 and the 52-week low is $4.50. The stock is currently 20.7% below its high.

Compare SGMT